Healthy elderly in clinical trials: how to define preclinical Alzheimer's Disease for clinical trial participation

Prins, S.

Citation

Prins, S. (2023, April 5). *Healthy elderly in clinical trials: how to define preclinical Alzheimer's Disease for clinical trial participation*. Retrieved from https://hdl.handle.net/1887/3590274

Note: To cite this publication please use the final published version (if applicable).

CURRICULUM VITEA

Samantha Prins (Hillegom, 1987) graduated from secondary school, Atheneum, in 2006 (Fioretti college, Lisse) and started her bachelor psychology at Leiden University in 2008. During her studies she followed courses at California State University East Bay in the USA. In 2012 she started her master Clinical Neuropsychology at Leiden University. She obtained her master's degree in 2014 after which she worked as a neuropsychologist at Leiden University Medical Centre (LUMC) at the 'Discontinuation of Antihypertensive Therapy in the Elderly' (DANTE) Leiden study at the department of psychiatry and the TRACK-ON Huntington's Disease study at the neurology department. Alongside the research at LUMC and her studies, Samantha also started working as a research assistant at Centre for Human Drug Research (CHDR) (2013). In 2015 she started as a project leader in the neurology group at CHDR. She performed early phase clinical trials focused on neurodegenerative diseases under supervision of prof. dr. Geert Jan Groeneveld and prof. dr. Joop van Gerven. In 2016/2017 a PhD topic was introduced. Her main scientific focus became (preclinical) Alzheimer's Disease with multicenter studies and CHDR funded studies which resulted in this thesis. Since 2022, Samantha works at Brain Research Center as a Senior Clinical Trial Start-Up Specialist.

LIST OF PUBLICATIONS

R. Alvarez-Jimenez, E.P. Hart, **S. Prins**, M. de Kam, J.M.A. van Gerven, A.F. Cohen, G.J. Groeneveld. Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses, 2018.

S. Simpraga, H.D. Mansvelder, G.J. Groeneveld, **S. Prins**, E.P. Hart, S. Poil, K. Linkenkaer-Hansen. An EEG nicotine acetylcholine index to assess the efficacy pf pro-cognitive compounds, 2018.

S. Prins, A. Zhuparris, G.J. Groeneveld. Usefulness of plasma amyloid as a prescreener for earliest Alzheimer pathological changes depends on the study population, 2019

T. Qin, **S. Prins**, G.J. Groeneveld, G. van Westen, H. E. de Vries, Y. C. Wong, L.J.M. Bischoff, E.C.M. de Lange. Utility of animal models to understand human Alzheimer's disease, using the mastermind research approach to avoid unnecessary further sacrifices of animals, 2020.

C. Bakker, T. Tasker, J. Liptrot, E.P. Hart, E.S. Klaassen, **S. Prins**, T.F. van der Doef, G.A. Brown, A. Brown, M. Congreve, M. Weir, F.H. Marshall, D.M. Cross, G.J. Groeneveld, P.J. Nathan. First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1-receptro partial agonist for the treatment of dementias, 2020.

S. Prins, A. Zhuparris, E.P. Hart, R.J. Doll, G.J. Groeneveld. A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trail participation, 2021.

C. Bakker*, **S. Prins***, J. Liptrot, E.P. Hart, E.S. Klaassen, G.A. Brown, A. Brown, M. Congreve, M. Weir, F.H. Marshall, J. Stevens, D.M. Cross, T. Tasker, P.J. Nathan, G.J. Groeneveld. Safety, pharmacokinetics and pharmaco-dynamics of HTL0009936, a selective muscarinic M1-acetylcholine receptor agonist: A randomized cross-over trial, 2021.

Elzinga W, **Prins S,** Borghans L, Gal P, Vargas G, Groeneveld G, Doll R. Detection of Clenbuterol-Induced Changes in Heart Rate Using At-Home Recorded Smartwatch Data: Randomized Controlled Trial, 2021

S. Prins, M.L. de Kam, C.E. Teunissen, G. Groeneveld. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease, 2022.